Ngā hua rapu - Nathanael S. Gray

Whakamahine hua
  1. 1
    The rise of degrader drugs

    The rise of degrader drugs mā Mingxing Teng, Nathanael S. Gray

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    The Evolving War on Cancer

    The Evolving War on Cancer mā Daniel A. Haber, Nathanael S. Gray, José Baselga

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Discovery of selective irreversible inhibitors for EGFR-T790M

    Discovery of selective irreversible inhibitors for EGFR-T790M mā Wenjun Zhou, Dalia Ercan, Pasi A. Jänne, Nathanael S. Gray

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase

    Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase mā Roxana E. Iacob, Jianming Zhang, Nathanael S. Gray, John R. Engen

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer

    Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer mā Wells S. Brown, Li Tan, Andrew Smith, Nathanael S. Gray, Michael K. Wendt

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Characterization of TAE684 as a potent LRRK2 kinase inhibitor

    Characterization of TAE684 as a potent LRRK2 kinase inhibitor mā Jinwei Zhang, Xianming Deng, Hwan Geun Choi, Dario R. Alessi, Nathanael S. Gray

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Activation of tyrosine kinases by mutation of the gatekeeper threonine

    Activation of tyrosine kinases by mutation of the gatekeeper threonine mā Mohammad Azam, Markus A. Seeliger, Nathanael S. Gray, John Kuriyan, George Q. Daley

    I whakaputaina 2008
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    mTOR mediated anti-cancer drug discovery

    mTOR mediated anti-cancer drug discovery mā Qingsong Liu, Carson C. Thoreen, Jinhua Wang, David M. Sabatini, Nathanael S. Gray

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    A Genome-Wide Overexpression Screen in Yeast for Small-Molecule Target Identification

    A Genome-Wide Overexpression Screen in Yeast for Small-Molecule Target Identification mā Hendrik Luesch, Tom Wu, Pingda Ren, Nathanael S. Gray, Peter G. Schultz, František Supek

    I whakaputaina 2005
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

    Acquired Resistance of Non–Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency mā Ultan McDermott, Raju V. Pusapati, James G. Christensen, Nathanael S. Gray, Jeff Settleman

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8

    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8 mā John M. Hatcher, Eric S. Wang, Liv Johannessen, Nicholas Kwiatkowski, Taebo Sim, Nathanael S. Gray

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells

    Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells mā Marta López‐Peláez, Douglas J. Lamont, Mark Peggie, Natalia Shpiro, Nathanael S. Gray, Philip Cohen

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors

    Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors mā Peter Canning, Li Tan, Kiki Chu, Sam W. Lee, Nathanael S. Gray, Alex N. Bullock

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML

    FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML mā Ellen Weisberg, Rosemary Barrett, Qingsong Liu, Richard M. Stone, Nathanael S. Gray, James D. Griffin

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

    Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines mā Antonio Calles, Nicholas Kwiatkowski, Bernard K. Cammarata, Dalia Ercan, Nathanael S. Gray, Pasi A. Jänne

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

    Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? mā Zheng Zhao, Hong Wu, Li Wang, Yi Liu, Stefan Knapp, Qingsong Liu, Nathanael S. Gray

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor

    Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor mā John M. Hatcher, Jinwei Zhang, Hwan Geun Choi, Genta Ito, Dario R. Alessi, Nathanael S. Gray

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics

    A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics mā A. Chaikuad, Eliana MC Tacconi, J. Zimmer, Yanke Liang, Nathanael S. Gray, Madalena Tarsounas, Stefan Knapp

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Systematic analysis of <scp>BRAF<sup>V</sup></scp><sup>600E</sup> melanomas reveals a role for <scp>JNK</scp>/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis

    Systematic analysis of <scp>BRAF<sup>V</sup></scp><sup>600E</sup> melanomas reveals a role for <scp>JNK</scp>/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis mā Mohammad Fallahi‐Sichani, Nathan J. Moerke, Mario Niepel, Tinghu Zhang, Nathanael S. Gray, Peter K. Sorger

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6

    Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6 mā Baishan Jiang, Eric S. Wang, Katherine A. Donovan, Yanke Liang, Eric S. Fischer, Tinghu Zhang, Nathanael S. Gray

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: